240 related articles for article (PubMed ID: 21748296)
1. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
El-Khoueiry AB; Rankin CJ; Ben-Josef E; Lenz HJ; Gold PJ; Hamilton RD; Govindarajan R; Eng C; Blanke CD
Invest New Drugs; 2012 Aug; 30(4):1646-51. PubMed ID: 21748296
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
Bengala C; Bertolini F; Malavasi N; Boni C; Aitini E; Dealis C; Zironi S; Depenni R; Fontana A; Del Giovane C; Luppi G; Conte P
Br J Cancer; 2010 Jan; 102(1):68-72. PubMed ID: 19935794
[TBL] [Abstract][Full Text] [Related]
3. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
El-Khoueiry AB; Rankin C; Siegel AB; Iqbal S; Gong IY; Micetich KC; Kayaleh OR; Lenz HJ; Blanke CD
Br J Cancer; 2014 Feb; 110(4):882-7. PubMed ID: 24423918
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
Williamson SK; Moon J; Huang CH; Guaglianone PP; LeBlanc M; Wolf GT; Urba SG
J Clin Oncol; 2010 Jul; 28(20):3330-5. PubMed ID: 20498388
[TBL] [Abstract][Full Text] [Related]
5. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.
Sridhar SS; Winquist E; Eisen A; Hotte SJ; McWhirter E; Tannock IF; Mukherjee SD; Wang L; Blattler C; Wright JJ; Moore MJ
Invest New Drugs; 2011 Oct; 29(5):1045-9. PubMed ID: 20191303
[TBL] [Abstract][Full Text] [Related]
7. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
Aragon-Ching JB; Jain L; Gulley JL; Arlen PM; Wright JJ; Steinberg SM; Draper D; Venitz J; Jones E; Chen CC; Figg WD; Dahut WL
BJU Int; 2009 Jun; 103(12):1636-40. PubMed ID: 19154507
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
Nimeiri HS; Oza AM; Morgan RJ; Huo D; Elit L; Knost JA; Wade JL; Agamah E; Vokes EE; Fleming GF
Gynecol Oncol; 2010 Apr; 117(1):37-40. PubMed ID: 20117828
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
[TBL] [Abstract][Full Text] [Related]
10. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
Beck J; Procopio G; Bajetta E; Keilholz U; Negrier S; Szczylik C; Bokemeyer C; Bracarda S; Richel DJ; Staehler M; Strauss UP; Mersmann S; Burock K; Escudier B
Ann Oncol; 2011 Aug; 22(8):1812-23. PubMed ID: 21324953
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.
Pinter M; Sieghart W; Reisegger M; Wrba F; Peck-Radosavljevic M
Wien Klin Wochenschr; 2011 Jan; 123(1-2):61-4. PubMed ID: 21240686
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Lam ET; Ringel MD; Kloos RT; Prior TW; Knopp MV; Liang J; Sammet S; Hall NC; Wakely PE; Vasko VV; Saji M; Snyder PJ; Wei L; Arbogast D; Collamore M; Wright JJ; Moley JF; Villalona-Calero MA; Shah MH
J Clin Oncol; 2010 May; 28(14):2323-30. PubMed ID: 20368568
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of sorafenib in metastatic thyroid cancer.
Kloos RT; Ringel MD; Knopp MV; Hall NC; King M; Stevens R; Liang J; Wakely PE; Vasko VV; Saji M; Rittenberry J; Wei L; Arbogast D; Collamore M; Wright JJ; Grever M; Shah MH
J Clin Oncol; 2009 Apr; 27(10):1675-84. PubMed ID: 19255327
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
Grignani G; Palmerini E; Dileo P; Asaftei SD; D'Ambrosio L; Pignochino Y; Mercuri M; Picci P; Fagioli F; Casali PG; Ferrari S; Aglietta M
Ann Oncol; 2012 Feb; 23(2):508-16. PubMed ID: 21527590
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
Zhang H; Dong B; Lu JJ; Yao X; Zhang S; Dai B; Shen Y; Zhu Y; Ye D; Huang Y
BMC Cancer; 2009 Jul; 9():249. PubMed ID: 19622166
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.
El-Khoueiry AB; Ramanathan RK; Yang DY; Zhang W; Shibata S; Wright JJ; Gandara D; Lenz HJ
Invest New Drugs; 2012 Jun; 30(3):1175-83. PubMed ID: 21424698
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
Bodnar L; Górnas M; Szczylik C
Gynecol Oncol; 2011 Oct; 123(1):33-6. PubMed ID: 21723597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
